Spread | 0.6832 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 0.01 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 14.2684 |
Open | 13.9484 |
1-Year Change | 1726.18% |
Day's Range | 13.9484 - 14.2884 |
Curis, Inc. is a biotechnology company focused on the development of therapeutics for the treatment of cancer. The Company’s drug candidates include CA-4948 and CI-8993. CA-4948 is an orally available small-molecule inhibitor of Interleukin-I receptor-associated kinase 4, which is undergoing testing in a Phase I open-label dose escalating clinical trial in patients with non-Hodgkin lymphomas. It is also conducting a Phase I open-label, single-arm dose escalating trial in patients with acute myeloid leukemia, and myelodysplastic syndromes. CI-8993 is a monoclonal antibody designed to antagonize the V-domain Ig suppressor of the T cell activation signaling pathway. The Company initiated a Phase Ia/Ib trial of CI-8993 in patients with solid tumors. The Company’s products pipeline includes Fimepinostat, CA-170, CA-327, and PD1/TIM3 Program.
BRIEF: For the fiscal year ended 31 December 2021, Curis, Inc. revenues decreased 2% to $10.6M. Net loss increased 52% to $45.4M. Revenues reflect Other revenue decrease of 100% to $1K. Higher net loss reflects Research & development Expenses B/F increase of 50% to $32M (expense), Other General and administrative, increase of 43% to $8M (expense), General and administrative expenses increase of 75% to $3.4M (expense).
Common Stock $.01 Par, 03/11, 125M auth., 77,397,663 issd., less 1,047,707 shs. in tres. @ $891K. Insiders own 2.72%. IPO 12/92, 3M shs. @ $7 by Montgomery Secs. *8/00, Co.merged with Ontogeny & Reprogenesis & chgd. name from Creative Biomolecules, Inc. FY'03&'04 are RES-Acct. Change. Summ. Qs reflects RES.